Establishment Labs Holdings AI Stock Analysis
Establishment Labs Holdings (3E0) AI Stock Analysis
Establishment Labs Holdings
(Frankfurt:3E0)
No summary available
Establishment Labs Holdings (3E0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 2.11B
- Dividend Yield
- ―
- Average Volume (3M)
- 127
- Price to Earnings (P/E)
- -55.3
- Beta (1Y)
- 0.67
- Revenue Growth
- 31.94%
- EPS Growth
- 57.98%
- Country
- Germany
- Employees
- 1,004
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Establishment Labs Holdings Business Overview & Revenue Model
Company Description
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-fill...
Establishment Labs Holdings Earnings Call Summary
The call was strongly positive, with substantial year-over-year revenue growth, major U.S. and minimally invasive momentum, improved adjusted profitability, first-ever positive free cash flow, raised 2026 guidance and a 25% growth outlook for 2027. The main challenges were seasonal sequential softness, Middle East weakness, lower-than-previously-guided gross margin, ongoing GAAP losses and uncertainty around the timing of reconstruction approval and hospital adoption.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised full year 2026 revenue guidance to more than $274 million from $269 million to $271 million, expects minimally invasive revenue to exceed $40 million versus previous guidance of more than $35 million, and expects full year adjusted gross margin of approximately 70.7%, adjusted operating expenses of $195 million to $200 million, positive adjusted EBITDA for the full year and positive free cash flow in fiscal 2027. Management expects growth in 2027 to be 25%, with 50 to 100 basis points of gross margin improvement, expects 500 surgeons trained on Preserve by year-end, and remains confident in mid-single-digit growth for the year in distributor markets; additional Motiva sizes are expected to be commercially available before year-end, with reconstruction approval expected either the end of this year or the beginning of next.
Establishment Labs Holdings Risk Analysis
Establishment Labs Holdings disclosed 66 risk factors in its most recent earnings report. Establishment Labs Holdings reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksEstablishment Labs Holdings Peers Comparison
Overall Rating
CNMD69Neutral
INMD69Neutral
AXGN68Neutral
BFLY67Neutral
IART44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | $1.51B | 20.90 | 7.07% | ― | 1.93% | 16.93% | |
| 69Neutral | $763.61M | 10.79 | 11.36% | ― | 2.50% | -43.86% | |
| 68Neutral | $3.34B | -86.05 | -11.34% | ― | 24.32% | -1274.47% | |
| 67Neutral | $1.63B | -29.04 | -28.22% | ― | 39.35% | 38.09% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $1.12B | 85.82 | 1.24% | ― | 0.84% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:3E0 | Establishment Labs Holdings | 61.38 | 23.78 | 63.24% | |
| CNMD | Conmed Corporation | 50.59 | 8.96 | 21.52% | |
| IART | Integra Lifesciences | 14.40 | 2.67 | 22.76% | |
| AXGN | AxoGen | 55.93 | 32.36 | 137.29% | |
| INMD | Inmode | 13.27 | -0.64 | -4.60% | |
| BFLY | Butterfly Network, Inc. | 6.08 | 4.11 | 208.63% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
